NCT07235293 2026-04-09
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Medical
Phase 2 Recruiting
Clinical Trials
13 trialsNCT06497985 2026-03-19
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT06992258 2026-03-17
FRUITION
Criterium, Inc.
Phase 2 Recruiting
NCT06562543 2026-02-27
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Takeda
Phase 4 Recruiting
NCT06195514 2026-01-30
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)
Takeda
No longer available
NCT05565417 2025-10-16
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
Phase 1/2 Active not recruiting
NCT04577963 2025-07-14
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04322539 2025-04-04
FRESCO-2
Hutchmed
Phase 3 Completed
NCT05368805 2022-10-06
Fruquintinib DDI Study With P-gp and BCRP Substrates
Hutchmed
Phase 1 Completed
NCT03977090 2021-02-10
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
Genor Biopharma Co., Ltd.
Phase 1 Unknown
NCT02196688 2020-06-16
Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Hutchmed
Phase 2 Completed
NCT01975077 2020-02-17
A Phase Ib Study of Fruquintinib in 3rd Line mCRC
Hutchmed
Phase 1/2 Completed
NCT02314819 2020-02-17
FRESCO
Hutchmed
Phase 3 Completed